UMOD GENI RS4293393 POLIMORFIZMINING ALLEL VA GENOTIP CHASTOTALARI TAQSIMOTINING SURUNKALI GLOMERULONEFRITLI BEMORLAR GURUHI VA NAZORAT GURUHI O'RTASIDAGI QIYOSIY TAHLILI
##article.subject##:
UMOD geni, rs4293393, surunkali glomerulonefrit, allel chastotasi, genotip taqsimoti, polimorfizm, genetik bog‘liqlik, xavfni baholash##article.abstract##
Ushbu tadqiqot UMOD genining rs4293393 polimorfik markeri allel va genotip chastotalarining surunkali glomerulonefrit (SGN) bilan og‘rigan bemorlar va nazorat guruhi o‘rtasidagi taqqoslamali tahliliga bag‘ishlangan. Tadqiqotning maqsadi allel variantlari va SGN rivojlanish xavfi o‘rtasidagi mumkin bo‘lgan bog‘liqlikni aniqlashdan iborat. Tahlil natijalariga ko‘ra, C alleli SGN bilan og‘rigan bemorlarda nazorat guruhiga qaraganda ko‘proq uchraydi (30,91% ga nisbatan 25,84%; OR = 1,28; 95% CI: 0,80–2,05), ammo statistik ahamiyatga erishilmadi (p = 0,356). T alleli esa aksincha, SGN bemorlari orasida kamroq uchraydi (69,09% ga nisbatan 74,16%; OR = 0,78; 95% CI: 0,49–1,24), lekin bu farq ham statistik jihatdan ahamiyatli emas (p = 0,356). Natijalar UMOD geni rs4293393 polimorfizmi va SGN rivojlanish xavfi o‘rtasida kuchsiz bog‘liqlik mavjudligini ko‘rsatadi, bu esa qo‘shimcha tadqiqotlarni talab qiladi.
Библиографические ссылки
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013 Sep;84(3):1-150.
Couser WG, Remuzzi G, Mendis S, Tonelli M. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int. 2011 Dec;80(12):1258-70. doi: 10.1038/ki.2011.368. Epub 2011 Oct 12.
Bellomo G., Venanzi S., Verdura C. et al. Association of uric acid with change in kidney function in healthy normotensive individuals. Am J Kidney Dis 2010; 56:264.
Johnson RJ, Nakagawa T, Jalal D, et al. Uric acid and chronic kidney disease: which is chasing which? Nephrol Dial Transplant. 2013 Sep;28(9):2221-8. doi: 10.1093/ndt/gft029. Epub 2013 Mar 29.
Kang DH, Chen W. Uric acid and chronic kidney disease: new understanding of an old problem. Semin Nephrol. 2011 Sep;31(5):447- 52. doi: 10.1016/j.semnephrol.2011.08.009.
Kratzer JT, Lanaspa MA, Murphy MN, et al. Evolutionary history and metabolic insights of ancient mammalian uricases. Proc Natl Acad Sci US A. 2014 Mar 11;111(10): 3763-8. doi: 10.1073/pnas.1320393111. Epub 2014 Feb 18.
Alimjanovich , R. Z., Maxammatkulovich , R. N., & Khikmatovich , K. K. (2022). Age Features of the Prevalence of Prostate Cancer in Uzbekistan. Central Asian Journal of Medical and Natural Science, 3(5), 154-157. Retrieved from
Rizaev Jasur , Rakhimov Nodir , Kodyrov Khamidullo , Shakhanova Shakhnoza . Study of prostate cancer death by regions of the republic of Uzbekistan.Journal of Biomedicine and Practice. 2022, vol . 7, issue 5, pp.202-210
Nodir RM, Shaxnoza SS, Farhod R. Development of new approaches in the treatment of metastatic renal cell carcinoma //Journal of research in health science. – 2020. – T. 5. – no. 4. – pp. 82-95.
ShSh Shakhanova , NM Rakhimov. Multimodal approach to the treatment of multiple osteogenic metastases of kidney and prostate cancer . Clinical and Experimental Oncology 2020, No. 4 Page 50-56.
Richette P, Latourte A, Bardin T. Cardiac and renal protective effects of uratelowering therapy. Rheumatology (Oxford). 2018 Jan 1; 57(suppl_1):i47-i50. doi: 10.1093/rheumatology/kex432.
Paul BJ, Anoopkumar K, Krishnan V. Asymptomatic hyperuricemia: is it time to intervene? Clin Rheumatol. 2017 Dec;36(12): 2637-2644. doi: 10.1007/s10067-017-3851-y. Epub 2017 Oct
